NCT00146562CompletedPhase 2
A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer
Harold J. Burstein, MD, PhD12 sites in 1 country135 target enrollmentStarted: July 2003Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 135
- Locations
- 12
- Primary Endpoint
- To determine the rate of febrile neutropenia in women treated with dose-dense adjuvant chemotherapy receiving pegfilgrastim every 2 weeks.
Study Overview
Brief Summary
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in chemotherapy recipients.
Detailed Description
- Patients will receive chemotherapy every 2 weeks for up to 8 cycles (spread out of approximately 16 weeks, total) of treatment. On the day of chemotherapy treatment patients may receive an injection of darbepoetin alfa in addition to chemotherapy if their red blood cell count is below normal levels.
- On the day after chemotherapy treatment, patients will receive an injection of pegfilgrastim. There is one pegfilgrastim shot given per treatment cycle, for a total of 8 injections. Once the patient has finished chemotherapy and the last of the pegfilgrastim shots, their participation in this trial will be complete.
- While on this study the following procedures will be performed: a physical exam will be done every 2 weeks, vital signs will be done every 2 weeks, and blood tests every 2 weeks.
- This study also involves a Quality of Life Questionnaire done at the beginning of study treatment, at 2 months, 4 months, 6 months, and 1 year after starting the study treatment.
- Patients will remain on this study unless they experience unacceptable side effects from any of the treatment drugs.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically confirmed breast cancer clinical stage I, II or III disease. Patients must be deemed of sufficient risk for tumor or recurrence
- •Patients may receive the defined adjuvant chemotherapy treatment either following definitive breast surgery or prior to definitive breast surgery
- •18 years of age or older
- •ECOG performance status 0 or 1
- •ANC > 1,500/uL
- •Hemoglobin > 9 g/dL
- •Platelets > 100,000/ul
- •Total bilirubin less than or equal to ULN
- •AST/ALT < 1.5 x ULN
- •Creatinine within normal institutional limits
- •PT/PTT < institutional upper limit of normal
- •LVEF > 50%
Exclusion Criteria
- •Previous cytotoxic chemotherapy or therapeutic radiation therapy
- •Pregnant or lactating women
- •Receiving any other investigational agents
- •Stage IV breast cancer
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to pegfilgrastim or darbepoetin
- •Previous exposure to G-CSF or pegfilgrastim or to recombinant erythropoetin-related growth factors.
- •On antibiotics within 72 hours of registration
- •Patients with immune deficiency who are at increased risk of lethal infections when treated with marrow-suppressive therapy, or HIV-positive patients receiving anti-retroviral therapy
- •Sickle cell disease
- •Known positive antibody response to any erythropoietic agent
- •Known hematologic diseases
- •Known history of hyperviscosity syndrome
- •Patients on lithium
- •RBC transfusion within past 4 weeks
Outcomes
Primary Outcomes
To determine the rate of febrile neutropenia in women treated with dose-dense adjuvant chemotherapy receiving pegfilgrastim every 2 weeks.
Time Frame: 2 years
Secondary Outcomes
- To determine the rate of RBC transfusion among patients treated with dose-dense adjuvant chemotherapy receiving darbepoetin every 2 weeks.(2 years)
Investigators
Harold J. Burstein, MD, PhD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Study Sites (12)
Loading locations...
Similar Trials
Completed
Phase 2
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)FeverNeutropeniaBreast CancerNCT00115414Amgen
Completed
Phase 4
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)Non-Hodgkin's LymphomaNCT02782845Hoffmann-La Roche53
Recruiting
Phase 2
Phase II study of pegfilgrastim as support to metastatic pancreatic cancer patients receiving FOLFIRINOXMetastatic pancreatic cancerJPRN-UMIN000017538ational Cancer Center Hospital35
Completed
Not Applicable
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)Lung CancerNon-Small Cell Lung CancerNCT00094822Amgen90
Completed
Phase 1
A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial InfarctionAcute Myocardial InfarctionNCT00215124The Cleveland Clinic